Table 2.
Multiple logistic regression for duration of glucocorticoid use in relation to mild, moderate, or severe cervical spine deformity at 10-year follow-up
| Multivariable odds ratio (95% confidence interval) | P-value | |
|---|---|---|
| Model 1 for cases of mild, moderate, or severe (AAS > 2 mm and/or SAS > 2 mm) (n1 = 272) | ||
| Duration of glucocorticoid use (years)† | 1.19 (1.03, 1.38) | 0.02 |
| Duration of glucocorticoid use (years) + average DAS score‡ | 1.17 (1.01, 1.36) | 0.04 |
| Model 2 for cases of moderate or severe (AAS ≥ 3 mm in flexion) (n2 = 109) | ||
| Duration of glucocorticoid use (years) † | 1.24 (0.92, 1.67) | 0.16 |
| Duration of glucocorticoid use (years) + average DAS score‡ | 1.26 (0.92, 1.72) | 0.16 |
| Model 3 for severe (AAS ≥ 5 mm in flexion or neutral) (n3 = 107) | ||
| Duration of glucocorticoid use (years) † | 1.57 (1.09, 2.28) | 0.02 |
| Duration of glucocorticoid use (years) + average DAS score‡ | 1.53 (1.05–2.24) | 0.03 |
†All three models for the three different outcomes of cervical spine deformity (AAS or SAS > 2 mm; AAS ≥ 3 mm; AAS ≥ 5 mm) were adjusted for age at baseline, sex (male or female), anti-CCP positivity, rheumatoid factor positivity, and baseline DAS score
‡Adjusted for the previous multivariable model plus mean DAS during the 10-year follow-up
*Abbreviations: DAS, Disease Activity Score; AAS, Atlantoaxial Subluxation; SAS, subaxial subluxation